Logo image of ABNX.PA

ABIONYX PHARMA SA (ABNX.PA) Stock Fundamental Analysis

EPA:ABNX - Euronext Paris - Matif - FR0012616852 - Common Stock - Currency: EUR

1.704  -0.03 (-1.73%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ABNX. ABNX was compared to 73 industry peers in the Biotechnology industry. The financial health of ABNX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ABNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABNX had negative earnings in the past year.
In the past year ABNX has reported a negative cash flow from operations.
In the past 5 years ABNX always reported negative net income.
ABNX had a negative operating cash flow in each of the past 5 years.
ABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFABNX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -32.35%, ABNX perfoms like the industry average, outperforming 47.95% of the companies in the same industry.
ABNX has a Return On Equity (-58.30%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -32.35%
ROE -58.3%
ROIC N/A
ROA(3y)-27.55%
ROA(5y)-25.53%
ROE(3y)-53.79%
ROE(5y)-48.87%
ROIC(3y)N/A
ROIC(5y)N/A
ABNX.PA Yearly ROA, ROE, ROICABNX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With a Gross Margin value of 18.55%, ABNX perfoms like the industry average, outperforming 47.95% of the companies in the same industry.
ABNX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ABNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.52%
GM growth 5YN/A
ABNX.PA Yearly Profit, Operating, Gross MarginsABNX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

4

2. Health

2.1 Basic Checks

ABNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABNX has been increased compared to 1 year ago.
Compared to 5 years ago, ABNX has more shares outstanding
The debt/assets ratio for ABNX has been reduced compared to a year ago.
ABNX.PA Yearly Shares OutstandingABNX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ABNX.PA Yearly Total Debt VS Total AssetsABNX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

ABNX has an Altman-Z score of 5.16. This indicates that ABNX is financially healthy and has little risk of bankruptcy at the moment.
ABNX has a Altman-Z score of 5.16. This is amongst the best in the industry. ABNX outperforms 83.56% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that ABNX is not too dependend on debt financing.
ABNX has a Debt to Equity ratio (0.25) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 5.16
ROIC/WACCN/A
WACC7.67%
ABNX.PA Yearly LT Debt VS Equity VS FCFABNX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 1.58 indicates that ABNX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.58, ABNX perfoms like the industry average, outperforming 41.10% of the companies in the same industry.
A Quick Ratio of 1.52 indicates that ABNX should not have too much problems paying its short term obligations.
ABNX has a Quick ratio (1.52) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.52
ABNX.PA Yearly Current Assets VS Current LiabilitesABNX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ABNX have decreased by -7.36% in the last year.
ABNX shows a decrease in Revenue. In the last year, the revenue decreased by -1.92%.
ABNX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 88.92% yearly.
EPS 1Y (TTM)-7.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.56%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y88.92%
Revenue growth 5YN/A
Sales Q2Q%-12.14%

3.2 Future

The Earnings Per Share is expected to decrease by -50.91% on average over the next years. This is quite bad
ABNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 68.30% yearly.
EPS Next Y-37.5%
EPS Next 2Y-8.97%
EPS Next 3Y9.56%
EPS Next 5Y-50.91%
Revenue Next Year4.35%
Revenue Next 2Y19.33%
Revenue Next 3Y59.17%
Revenue Next 5Y68.3%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ABNX.PA Yearly Revenue VS EstimatesABNX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M
ABNX.PA Yearly EPS VS EstimatesABNX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABNX.PA Price Earnings VS Forward Price EarningsABNX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABNX.PA Per share dataABNX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.97%
EPS Next 3Y9.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIONYX PHARMA SA

EPA:ABNX (8/5/2025, 7:00:00 PM)

1.704

-0.03 (-1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)09-25 2025-09-25
Inst Owners4.67%
Inst Owner ChangeN/A
Ins Owners32.61%
Ins Owner ChangeN/A
Market Cap59.52M
Analysts85
Price Target10.97 (543.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)4.35%
Revenue NY rev (3m)4.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.08
P/FCF N/A
P/OCF N/A
P/B 7.92
P/tB 28.88
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.13
BVpS0.22
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.35%
ROE -58.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.55%
FCFM N/A
ROA(3y)-27.55%
ROA(5y)-25.53%
ROE(3y)-53.79%
ROE(5y)-48.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.52%
GM growth 5YN/A
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.3%
Cap/Sales 1.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.52
Altman-Z 5.16
F-Score4
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)90.3%
Cap/Depr(5y)216.62%
Cap/Sales(3y)2.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.56%
EPS Next Y-37.5%
EPS Next 2Y-8.97%
EPS Next 3Y9.56%
EPS Next 5Y-50.91%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y88.92%
Revenue growth 5YN/A
Sales Q2Q%-12.14%
Revenue Next Year4.35%
Revenue Next 2Y19.33%
Revenue Next 3Y59.17%
Revenue Next 5Y68.3%
EBIT growth 1Y-30.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-51.85%
EBIT Next 3Y-7.99%
EBIT Next 5Y-61.71%
FCF growth 1Y3.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.73%
OCF growth 3YN/A
OCF growth 5YN/A